Crohn’s Disease
23 original drugs 23
Novel Drugs
3
Reformulations
0
Active Trials
6
Drug Targets
Market Leaders
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Crohn’s Disease
Novel Drugs by Company (New molecular entities)
Amgen 3 drugs
+8 more companies
Reformulations (3 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Drug Targets
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs